Under the epidemic situation, the pharmaceutical sector continued to be strong, Yisheng pharmaceutical industry rose 7.35%

On February 4, the Shanghai and Shenzhen stock markets opened lower and went higher today, with market sentiment clearly picking up As of the closing, the Shanghai index rose 1.34% to 2783 points, the Shenzhen Composite Index rose 3.17% to 10089 points, and the pharmaceutical and biological index rose 3.71% to 8370.50 On the market, the pharmaceutical sector all strengthened, in which Yisheng Pharmaceutical (002566) shares rose 7.35% to close at 8.03 yuan / share, further enlarging the volume On the news, on February 3, 3235 new confirmed cases, 492 new severe cases and 64 new deaths were reported in China At present, novel coronavirus will usher in the outbreak period "Fewer people go out, wash hands frequently and wear masks" have been popular among the people On February 3, with the support of the Ministry of science and technology, the "National Science and technology emergency project - clinical research on Integrated Traditional Chinese and Western medicine for the prevention and treatment of pneumonia caused by new coronavirus" was officially launched China's each one has his good points in the novel coronavirus infection, Zhang Boli, a member of the Chinese Academy of engineering who is responsible for the project At present, there is no effective drug for the treatment of pneumonia, so it is particularly important to treat patients with Chinese and Western cooperation " According to the public information, Yisheng Pharmaceutical (002566) is mainly engaged in the R & D, manufacturing and sales of proprietary Chinese medicine and large health products After years of research, the company has developed the national pharmaceutical quasi brand products with ginseng root, ginseng stem and leaf, ginseng flower and ginseng fruit as the main raw materials It is the first modern pharmaceutical enterprise in the pharmaceutical industry to realize the whole plant development of ginseng A novel coronavirus diagnosis and treatment plan released by the National Health Protection Commission and the State Administration of traditional Chinese medicine has been tried out in the fourth edition, including the Shengmai injection, the leading product of Yisheng Pharmaceutical (002566) Ye Yin, an analyst at Ping An Securities, said that in the short term, companies related to the epidemic can be properly concerned, and long-term targets in line with the direction of industrial transformation and upgrading are still recommended We analyzed the performance of the Hong Kong stock market during the Spring Festival 2020 and the A-share market during the SARS in 2003 The pharmaceutical industry failed to significantly outperform the market during the epidemic period, which was more a structural opportunity for related concept stocks As the outbreak during the Spring Festival exceeds market expectations, it is expected that the concept stocks related to the outbreak may still rise in stages.